TEVA vs. VEEV: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at TEVA and VEEV, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
TEVA trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, VEEV is a standard domestic listing.
| Symbol | TEVA | VEEV |
|---|---|---|
| Company Name | Teva Pharmaceutical Industries Limited | Veeva Systems Inc. |
| Country | Israel | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Health Care Technology |
| Market Capitalization | 21.18 billion USD | 46.41 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | February 16, 1982 | October 16, 2013 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of TEVA and VEEV by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | TEVA | VEEV |
|---|---|---|
| 5-Day Price Return | 2.57% | 3.29% |
| 13-Week Price Return | 3.23% | 18.52% |
| 26-Week Price Return | 5.25% | 21.30% |
| 52-Week Price Return | -6.33% | 46.19% |
| Month-to-Date Return | 11.87% | -0.06% |
| Year-to-Date Return | -22.74% | 35.09% |
| 10-Day Avg. Volume | 1.50M | 0.98M |
| 3-Month Avg. Volume | 2.24M | 1.34M |
| 3-Month Volatility | 24.94% | 42.44% |
| Beta | 0.82 | 0.97 |
Profitability
Return on Equity (TTM)
TEVA
-2.58%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
TEVA has a negative Return on Equity of -2.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
VEEV
13.74%
Health Care Technology Industry
- Max
- 47.95%
- Q3
- 35.17%
- Median
- 13.74%
- Q1
- 11.05%
- Min
- 11.05%
VEEV’s Return on Equity of 13.74% is on par with the norm for the Health Care Technology industry, indicating its profitability relative to shareholder equity is typical for the sector.
Net Profit Margin (TTM)
TEVA
-0.95%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
TEVA has a negative Net Profit Margin of -0.95%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
VEEV
27.34%
Health Care Technology Industry
- Max
- 51.50%
- Q3
- 45.32%
- Median
- 27.34%
- Q1
- 14.21%
- Min
- 14.21%
VEEV’s Net Profit Margin of 27.34% is aligned with the median group of its peers in the Health Care Technology industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
TEVA
5.38%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
TEVA’s Operating Profit Margin of 5.38% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
VEEV
26.97%
Health Care Technology Industry
- Max
- 73.15%
- Q3
- 56.55%
- Median
- 26.97%
- Q1
- 22.10%
- Min
- 22.10%
VEEV’s Operating Profit Margin of 26.97% is around the midpoint for the Health Care Technology industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | TEVA | VEEV |
|---|---|---|
| Return on Equity (TTM) | -2.58% | 13.74% |
| Return on Assets (TTM) | -0.40% | 11.20% |
| Net Profit Margin (TTM) | -0.95% | 27.34% |
| Operating Profit Margin (TTM) | 5.38% | 26.97% |
| Gross Profit Margin (TTM) | 50.88% | 75.50% |
Financial Strength
Current Ratio (MRQ)
TEVA
1.06
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
TEVA’s Current Ratio of 1.06 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
VEEV
4.60
Health Care Technology Industry
- Max
- 7.04
- Q3
- 7.01
- Median
- 4.60
- Q1
- 2.96
- Min
- 0.31
VEEV’s Current Ratio of 4.60 aligns with the median group of the Health Care Technology industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
TEVA
2.52
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.52, TEVA operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
VEEV
0.00
Health Care Technology Industry
- Max
- 0.06
- Q3
- 0.05
- Median
- 0.01
- Q1
- 0.00
- Min
- 0.00
Falling into the lower quartile for the Health Care Technology industry, VEEV’s Debt-to-Equity Ratio of 0.00 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
TEVA
-0.38
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
TEVA has a negative Interest Coverage Ratio of -0.38. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
VEEV
169.00
Health Care Technology Industry
- Max
- 224.12
- Q3
- 222.84
- Median
- 219.00
- Q1
- 181.50
- Min
- 169.00
In the lower quartile for the Health Care Technology industry, VEEV’s Interest Coverage Ratio of 169.00 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
Financial Strength at a Glance
| Symbol | TEVA | VEEV |
|---|---|---|
| Current Ratio (MRQ) | 1.06 | 4.60 |
| Quick Ratio (MRQ) | 0.68 | 4.54 |
| Debt-to-Equity Ratio (MRQ) | 2.52 | 0.00 |
| Interest Coverage Ratio (TTM) | -0.38 | 169.00 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
TEVA
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
TEVA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
VEEV
0.00%
Health Care Technology Industry
- Max
- 1.12%
- Q3
- 0.62%
- Median
- 0.12%
- Q1
- 0.00%
- Min
- 0.00%
VEEV currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
TEVA
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
TEVA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
VEEV
0.00%
Health Care Technology Industry
- Max
- 101.92%
- Q3
- 72.22%
- Median
- 42.51%
- Q1
- 0.00%
- Min
- 0.00%
VEEV has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | TEVA | VEEV |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
TEVA
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for TEVA is currently unavailable.
VEEV
59.28
Health Care Technology Industry
- Max
- 343.51
- Q3
- 272.61
- Median
- 54.67
- Q1
- 36.04
- Min
- 31.57
VEEV’s P/E Ratio of 59.28 is within the middle range for the Health Care Technology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
TEVA
1.25
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, TEVA’s P/S Ratio of 1.25 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
VEEV
16.21
Health Care Technology Industry
- Max
- 176.90
- Q3
- 98.12
- Median
- 16.38
- Q1
- 4.49
- Min
- 0.00
VEEV’s P/S Ratio of 16.21 aligns with the market consensus for the Health Care Technology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
TEVA
2.80
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
TEVA’s P/B Ratio of 2.80 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
VEEV
6.13
Health Care Technology Industry
- Max
- 117.60
- Q3
- 90.72
- Median
- 8.09
- Q1
- 3.83
- Min
- 3.06
VEEV’s P/B Ratio of 6.13 is within the conventional range for the Health Care Technology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | TEVA | VEEV |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 59.28 |
| Price-to-Sales Ratio (TTM) | 1.25 | 16.21 |
| Price-to-Book Ratio (MRQ) | 2.80 | 6.13 |
| Price-to-Free Cash Flow Ratio (TTM) | 18.48 | 39.03 |